KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer
- PMID: 19297803
Item in Clipboard
KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer
Technol Eval Cent Assess Program Exec Summ.
2009 Jan.
No abstract available
Similar articles
-
Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.Oncology (Williston Park). 2014 Feb;28(2):96. Oncology (Williston Park). 2014. PMID: 24701695 No abstract available.
-
KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.Clin Adv Hematol Oncol. 2008 Dec;6(12):1-13, 14-6. Clin Adv Hematol Oncol. 2008. PMID: 19378369
-
[Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].Lakartidningen. 2010 Feb 3-9;107(5):255-9. Lakartidningen. 2010. PMID: 20297566 Swedish. No abstract available.
-
[Some problems facing the molecular targeting therapy for colorectal cancer].Zhonghua Zhong Liu Za Zhi. 2009 May;31(5):321-3. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 19799077 Review. Chinese. No abstract available.
-
Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status.Cancer Treat Rev. 2010 Feb;36 Suppl 1:S15-6. doi: 10.1016/S0305-7372(10)70003-7. Cancer Treat Rev. 2010. PMID: 20189055 Review. No abstract available.
Cited by
-
Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update.Genet Med. 2013 Jan;15(1):14-24. doi: 10.1038/gim.2012.106. Epub 2012 Sep 6. Genet Med. 2013. PMID: 22955111 Free PMC article. Review.
-
Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.Am J Cancer Res. 2011 May 15;1(5):650-62. Am J Cancer Res. 2011. PMID: 21779535 Free PMC article.
-
Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.Clin Pharmacol Ther. 2011 Jul;90(1):25-7. doi: 10.1038/clpt.2011.71. Clin Pharmacol Ther. 2011. PMID: 21691271 Free PMC article.
-
Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.Clin Pharmacol Ther. 2014 Apr;95(4):394-402. doi: 10.1038/clpt.2013.226. Epub 2014 Feb 19. Clin Pharmacol Ther. 2014. PMID: 24398597 Free PMC article. Review.
-
Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.Oncologist. 2010;15(2):157-67. doi: 10.1634/theoncologist.2009-0221. Epub 2010 Feb 4. Oncologist. 2010. PMID: 20133499 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous